Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones

Cancer Letters

Volumn 323, Issue 1, 2012, Pages 77-87

  Cavazzoni, Andrea ^a   Bonelli, Mara A ^a   Fumarola, Claudia ^a   La Monica, Silvia ^a   Airoud, Kinda ^a   Bertoni, Ramona ^a   Alfieri, Roberta R ^a   Galetti, Maricla ^a   Tramonti, Stefano ^a   Galvani, Elena ^a   Harris, Adrian L ^b   Martin, Lesley Ann ^c   Andreis, Daniele ^d   Bottini, Alberto ^d   Generali, Daniele ^d   Petronini, Pier Giorgio ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d CREMONA HOSPITAL   (Italy)

Author keywords

AKT; Breast; Letrozole; MTOR; Resistance

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; AROMATASE; DASATINIB; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; EVEROLIMUS; FULVESTRANT; GROWTH FACTOR RECEPTOR; LAPATINIB; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; WORTMANNIN;

AGED; AKT1 GENE; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL CLONE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LONG TERM EXPOSURE; MOLECULAR DYNAMICS; MOLECULARLY TARGETED THERAPY; MTOR GENE; PHENOTYPIC VARIATION; PI3KCA GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT DURATION; TUMOR GENE; UPREGULATION;

AGED; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMIDAZOLES; IMMUNOSUPPRESSIVE AGENTS; NEOADJUVANT THERAPY; NITRILES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; QUINOLINES; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TRIAZOLES;

EID: 84861823850     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.03.034     Document Type: Article

References (45)

1. Smith I.E., Dowsett M. Aromatase inhibitors in breast cancer. N. Engl. J. Med. 2003, 348:2431-2442.
2. Baum M., Budzar A.U., Cuzick J., Forbes J., Houghton J.H., Klijn J.G., Sahmoud T. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002, 359:2131-2139.
3. Johnston S.R. Enhancing the efficacy of hormonal agents with selected targeted agents. Clin. Breast Cancer 2009, 9(Suppl 1):S28-36.
4. Yue W., Fan P., Wang J., Li Y., Santen R.J. Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. J. Steroid Biochem. Mol. Biol. 2007, 106:102-110.
5. Martin L.A., Farmer I., Johnston S.R., Ali S., Marshall C., Dowsett M. Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J. Biol. Chem. 2003, 278:30458-30468.
6. Massarweh S., Osborne C.K., Creighton C.J., Qin L., Tsimelzon A., Huang S., Weiss H., Rimawi M., Schiff R. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 2008, 68:826-833.
7. Boulay A., Rudloff J., Ye J., Zumstein-Mecker S., O'Reilly T., Evans D.B., Chen S., Lane H.A. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin. Cancer Res. 2005, 11:5319-5328.
8. Johnston S.R., Martin L.A., Head J., Smith I., Dowsett M. Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance. J. Steroid Biochem. Mol. Biol. 2005, 95:173-181.
9. Nicholson R.I., Staka C., Boyns F., Hutcheson I.R., Gee J.M. Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy. Endocr. Relat. Cancer 2004, 11:623-641.
10. Aguilar H., Sole X., Bonifaci N., Serra-Musach J., Islam A., Lopez-Bigas N., Mendez-Pertuz M., Beijersbergen R.L., Lazaro C., Urruticoechea A., Pujana M.A. Biological reprogramming in acquired resistance to endocrine therapy of breast cancer. Oncogene 2010, 29:6071-6083.
11. Beeram M., Tan Q.T., Tekmal R.R., Russell D., Middleton A., DeGraffenried L.A. AKT-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann. Oncol. 2007, 18:1323-1328.
12. Bonelli M.A., Fumarola C., Alfieri R.R., La Monica S., Cavazzoni A., Galetti M., Gatti R., Belletti S., Harris A.L., Fox S.B., Evans D.B., Dowsett M., Martin L.A., Bottini A., Generali D., Petronini P.G. Synergistic activity of letrozole and sorafenib on breast cancer cells. Breast Cancer Res. Treat. 2010, 124:79-88.
13. Cavazzoni A., Petronini P.G., Galetti M., Roz L., Andriani F., Carbognani P., Rusca M., Fumarola C., Alfieri R., Sozzi G. Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line. Oncogene 2004, 23:8439-8446.
14. Gillies R.J., Didier N., Denton M. Determination of cell number in monolayer cultures. Anal. Biochem. 1986, 159:109-113.
15. Fumarola C., La Monica S., Alfieri R.R., Borra E., Guidotti G.G. Cell size reduction induced by inhibition of the mTOR/S6K-signaling pathway protects Jurkat cells from apoptosis. Cell Death Differ. 2005, 12:1344-1357.
16. Lephart E.D., Simpson E.R. Assay of aromatase activity. Methods Enzymol. 1991, 206:477-483.
17. Patel N.S., Li J.L., Generali D., Poulsom R., Cranston D.W., Harris A.L. Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res. 2005, 65:8690-8697.
18. Generali D., Fox S.B., Brizzi M.P., Allevi G., Bonardi S., Aguggini S., Milani M., Bersiga A., Campo L., Dionisio R., Vergoni F., Giardini R., Dogliotti L., Bottini A., Harris A.L., Berruti A. Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer. Clin. Cancer Res. 2008, 14:2673-2680.
19. Bottini A., Generali D., Brizzi M.P., Fox S.B., Bersiga A., Bonardi S., Allevi G., Aguggini S., Bodini G., Milani M., Dionisio R., Bernardi C., Montruccoli A., Bruzzi P., Harris A.L., Dogliotti L., Berruti A. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J. Clin. Oncol. 2006, 24:3623-3628.
20. Goldoni M., Johansson C. A mathematical approach to study combined effects of toxicants in vitro: evaluation of the Bliss independence criterion and the Loewe additivity model. Toxicol. In Vitro 2007, 21:759-769.
21. Sam M.R., Elliott B.E., Mueller C.R. A novel activating role of SRC and STAT3 on HGF transcription in human breast cancer cells. Mol. Cancer 2007, 6:69.
22. Wong N.C., Mueller B.M., Barbas C.F., Ruminski P., Quaranta V., Lin E.C., Smith J.W. Alphav integrins mediate adhesion and migration of breast carcinoma cell lines. Clin. Exp. Metast. 1998, 16:50-61.
23. Carracedo A., Ma L., Teruya-Feldstein J., Rojo F., Salmena L., Alimonti A., Egia A., Sasaki A.T., Thomas G., Kozma S.C., Papa A., Nardella C., Cantley L.C., Baselga J., Pandolfi P.P. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 2008, 118:3065-3074.
24. Dowsett M., Smith I.E., Ebbs S.R., Dixon J.M., Skene A., A'Hern R., Salter J., Detre S., Hills M., Walsh G. IMPACT Trialists Group. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J. Natl. Cancer Inst. 2007, 99:167-170.
25. Chen S., Masri S., Hong Y., Wang X., Phung S., Yuan Y.C., Wu X. New experimental models for aromatase inhibitor resistance. J. Steroid Biochem. Mol. Biol. 2007, 106:8-15.
26. Jelovac D., Sabnis G., Long B.J., Macedo L., Goloubeva O.G., Brodie A.M. Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole. Cancer Res. 2005, 65:5380-5389.
27. Masri S., Phung S., Wang X., Chen S. Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines. J. Steroid Biochem. Mol. Biol. 2010, 118:277-282.
28. Behrens D., Lykkesfeldt A.E., Fichtner I. The mTOR pathway inhibitor RAD001 (everolimus) is highly efficacious in tamoxifen-sensitive and resistant breast cancer xenografts. Targ. Oncol. 2007, 2:135-144.
29. deGraffenried L.A., Friedrichs W.E., Russell D.H., Donzis E.J., Middleton A.K., Silva J.M., Roth R.A., Hidalgo M. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant AKT Activity. Clin. Cancer Res. 2004, 10:8059-8067.
30. Carriere A., Cargnello M., Julien L.A., Gao H., Bonneil E., Thibault P., Roux P.P. Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation. Curr. Biol. 2008, 18:1269-1277.
31. Ma L., Chen Z., Erdjument-Bromage H., Tempst P., Pandolfi P.P. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 2005, 121:179-193.
32. Roux P.P., Ballif B.A., Anjum R., Gygi S.P., Blenis J. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc. Natl. Acad. Sci. USA 2004, 101:13489-13494.
33. Staka C.M., Nicholson R.I., Gee J.M. Acquired resistance to oestrogen deprivation: role for growth factor signalling kinases/oestrogen receptor cross-talk revealed in new MCF-7X model. Endocr. Relat. Cancer 2005, 12(Suppl 1):S85-97.
34. Santen R.J., Song R.X., Zhang Z., Kumar R., Jeng M.H., Masamura A., Lawrence J., Berstein L., Yue W. Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity. Endocr. Relat. Cancer 2005, 12(Suppl 1):S61-73.
35. Sabnis G.J., Jelovac D., Long B., Brodie A. The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. Cancer Res. 2005, 65:3903-3910.
36. Miller W.R., Larionov A. Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole. Breast Cancer Res. 2010, 12:R52.
37. Sachdeva M., Wu H., Ru P., Hwang L., Trieu V., Mo Y.Y. MicroRNA-101-mediated AKT activation and estrogen-independent growth. Oncogene 2011, 30:822-831.
38. Baselga J., Semiglazov V., van Dam P., Manikhas A., Bellet M., Mayordomo J., Campone M., Kubista E., Greil R., Bianchi G., Steinseifer J., Molloy B., Tokaji E., Dixon J., Jonat W., Rugo H. Phase II double-blind randomized trial of daily oral RAD001 (everolimus) plus letrozole (LET) or placebo (P) plus LET as neoadjuvant therapy for ER+ breast cancer [Abstract]. Breast Cancer Res. Treat. 2007, 106:S107.
39. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., Lane H., Hofmann F., Hicklin D.J., Ludwig D.L., Baselga J., Rosen N. MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates AKT. Cancer Res. 2006, 66:1500-1508.
40. Xu C.X., Zhao L., Yue P., Fang G., Tao H., Owonikoko T.K., Ramalingam S.S., Khuri F.R., Sun S.Y. Augmentation of NVP-BEZ235's anticancer activity against human lung cancer cells by blockage of autophagy. Cancer Biol. Ther. 2011, 12:549-555.
41. Serra V., Markman B., Scaltriti M., Eichhorn P.J., Valero V., Guzman M., Botero M.L., Llonch E., Atzori F., Di Cosimo S., Maira M., Garcia-Echeverria C., Parra J.L., Arribas J., Baselga J. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 2008, 68:8022-8030.
42. Brachmann S.M., Hofmann I., Schnell C., Fritsch C., Wee S., Lane H., Wang S., Garcia-Echeverria C., Maira S.M. Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc. Natl. Acad. Sci. USA 2009, 106:22299-22304.
43. Sanchez C.G., Ma C.X., Crowder R.J., Guintoli T., Phommaly C., Gao F., Lin L., Ellis M.J. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res. 2011, 13:R21.
44. C. Brunner-Kubath, W. Shabbir, V. Saferding, R. Wagner, C.F. Singer, P. Valent, W. Berger, B. Marian, C.C. Zielinski, M. Grusch, T.W. Grunt, The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells. Breast Cancer Res Treat (2010, in press).
45. Crowder R.J., Phommaly C., Tao Y., Hoog J., Luo J., Perou C.M., Parker J.S., Miller M.A., Huntsman D.G., Lin L., Snider J., Davies S.R., Olson J.A., Watson M.A., Saporita A., Weber J.D., Ellis M.J. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res. 2009, 69:3955-3962.